A double-blind controlled trial of the effect of sodium cromoglycate in preventing relapse in ulcerative colitis
Open Access
- 1 July 1981
- journal article
- research article
- Published by Oxford University Press (OUP) in Postgraduate Medical Journal
- Vol. 57 (669) , 436-438
- https://doi.org/10.1136/pgmj.57.669.436
Abstract
Summary: A double-blind controlled trial of the effect of sodium cromoglycate (SCG) in preventing relapse in ulcerative colitis has been completed in 100 subjects. In patients already taking sulphasalazine, SCG did not prove to be of any additional benefit. However, in patients not on any other maintenance therapy, the relapse rate was 40% for SCG as compared with 75% for placebo. A large study of the effect of SCG in patients intolerant of sulphasalazine is indicated.This publication has 7 references indexed in Scilit:
- Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.Gut, 1980
- COMPARISON OF DISODIUM CROMOGLYCATE AND SULPHASALAZINE AS MAINTENANCE THERAPY FOR ULCERATIVE COLITISThe Lancet, 1979
- Controlled trial of disodium cromoglycate in chronic persistent ulcerative colitis.Gut, 1978
- Comparative trial of sulphasalazine and oral sodium cromoglycate in the maintenance of remission in ulcerative colitis.Gut, 1978
- TREATMENT OF ULCERATIVE COLITIS WITH ORAL DISODIUM CROMOGLYCATEThe Lancet, 1976
- Disodium cromoglycate in the treatment of chronic proctitis.Gut, 1975
- A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin)Gut, 1973